GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows:

Conference call details:

Date:

August 6, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

Register Here

Dial-in number:

(888) 880-3330 (Domestic) or

(+1) (646) 357-8766 (International)

Webcast:

ir.novavax.com/events

GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. 

GAITHERSBURG, Md., June 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid® and Fluzone HD, respectively. This cohort was designed to provide descriptive data on three flu strains (H1N1, H3N2, B) and SARS-CoV-2 (COVID-19) to inform a future registrational Phase 3 program.

GAITHERSBURG, Md., May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conferences:

Jefferies Global Healthcare Conference:

Fireside Chat

Date:

Wednesday, June 4, 2025

Time:

2:00 – 2:30 p.m. Eastern Time (ET)

Location:           

New York, NY

Goldman Sachs 46th Annual Global Healthcare Conference:

Presentation

Date:

Wednesday, June 11, 2025

Time:

2:00 – 2:35 p.m. ET

Location:

Miami Beach, FL

A webcast of the fireside chat and presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcasts will be available for 30 days.

GAITHERSBURG, Md., May 19, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, diabetes, obesity, smoking).1 Achievement of the U.S. license approval has triggered a $175 million milestone payment from Sanofi.

GAITHERSBURG, Md., May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Conference Details:

Fireside Chat

Date:

Wednesday, May 14, 2025

Time:

3:00 – 3:30 p.m. Pacific Time (PT)

Location:

Las Vegas, NV

Conference

Event:

Investor Meetings

Date:

Wednesday, May 14, 2025

A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.

GAITHERSBURG, Md., May 5, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) with Takeda. The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals and royalties on net sales earned every season moving forward.

GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows:

Conference call details:

Date:

May 8, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

https://emportal.ink/43UHjFq

Dial-in number:

(800) 836-8184 (Domestic) or

(+1) (646) 357-8785 (International)

Webcast:

ir.novavax.com/events

GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors.

"Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corporate growth strategy focused on forging strategic partnerships for our R&D assets and our Matrix-M® adjuvant." 

GAITHERSBURG, Md., April 15, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah study (Study of Healthcare Workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 Vaccine Doses in Utah) that showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) targeting the JN.1 strain resulted in fewer and less severe reactogenicity symptoms, when compared with the Pfizer-BioNTech mRNA 2024-2025 vaccine. This real-world study conducted between September and December 2024 in partnership with the University of Utah Health, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients of Novavax's vaccine. The results were presented today at the Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025.

GAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed John Shiver, PhD, to its board as an independent director.

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences:

TD Cowen 45th Annual Health Care Conference:

Fireside Chat

Date:

Tuesday, March 4, 2025

Time:

9:10 – 9:40 a.m. Eastern Time (ET)

Location:

Boston, MA

Conference

Event:

Investor Meetings

Date:

Tuesday, March 4, 2025

Leerink Partners 2025 Global Healthcare Conference:

Presentation

Date:

Tuesday, March 11, 2025

Time:

3:40 – 4:10 p.m. ET

Location:

Miami Beach, FL

Conference

Event:

Investor Meetings

Date:

Tuesday, March 11, 2025

Jefferies Biotech on the Beach Summit:

Conference

Event:

Investor Meetings

Date:

Wednesday, March 12, 2025

Location:

Miami Beach, FL

GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows:

Conference call details:

Date:

February 27, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:

https://emportal.ink/3PsP11e

Dial-in number:

(800) 836-8184 (Domestic) or

(+1) (646) 357-8785 (International)

Webcast:

  ir.novavax.com/events

GAITHERSBURG, Md., Dec. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi.

GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate the immunogenicity and safety of the CIC and stand-alone seasonal influenza vaccine candidates compared to Novavax's updated 2024-2025 COVID-19 vaccine (NVX-CoV2705) and a licensed seasonal influenza vaccine comparator in adults aged 65 and older.

GAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. The agreement includes a transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufacturing facility with support buildings, along with the existing workforce and all related and required infrastructure.

NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether Novavax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

GAITHERSBURG, Md., Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Company granted a non- qualified stock option and restricted stock units to Ruxandra Draghia-Akli, MD, PhD, its newly appointed Executive Vice President and Head of Research & Development, as a material inducement for her entry into employment with Novavax, effective as of November 11, 2024 (the "grant date"). These awards were approved by the Compensation Committee of Novavax and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Novavax, Inc. 2023 Inducement Plan.